If they eyes are the window to your soul, make them as inviting as possible.
With Latisse, thin or inadequate eyelashes can be a thing of the past. LATISSE® is the first and only FDA-approved product that can actually increase eyelash growth. For your Denver Latisse treatment, visit Body Massage Wellness Spa.
LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information
LATISSE® is the first and only FDA-approved product indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
HOW IS LATISSE® SOLUTION DIFFERENT FROM OTHER EYELASH GROWTH PRODUCTS?| Only LATISSE® has been approved by the FDA as a prescription treatment to grow eyelashes in people with inadequate or not enough eyelashes.
HOW DOES IT WORK? | LATISSE® is believed to prolong the anagen (active growth) phase.1 The exact way it works is unknown
HOW DO PATIENTS APPLY THE PRODUCT? | Patients should be informed that LATISSE® should be applied every night using only the accompanying sterile applicators. They should start by ensuring their face is clean, all makeup is removed, and their contact lenses removed (if applicable). Then carefully place one drop of LATISSE® solution on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. If any LATISSE® solution gets into the eye proper, it will not cause harm. The eye should not be rinsed. Patients should be informed not to apply to the lower eyelash line. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material.
HOW SHOULD PATIENTS HANDLE THE BOTTLE AND APPLICATORS? | Patients should be instructed that the LATISSE® bottle must be maintained intact and to avoid allowing the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination of the bottle or applicator by common bacteria known to cause ocular infections. Patients should also be instructed to only use the applicator supplied with the product once and then discard since reuse could result in using a contaminated applicator. Serious infections may result from using contaminated solutions or applicators.
WHAT IS HYPOTRICHOSIS OF THE EYELASHES? | Hypotrichosis is another name for having inadequate or not enough eyelashes
WHO SHOULD NOT USE LATISSE® SOLUTION? | Patients should not use LATISSE® solution if they are allergic to one of its ingredients.
WHOM SHOULD PATIENTS TELL IF THEY’RE USING LATISSE®? | Patients should tell their physician they are using LATISSE® especially if they have a history of eye pressure problems. They should also tell anyone conducting an eye pressure screening that they are using LATISSE® solution.
ARE THERE ANY SPECIAL WARNINGS ASSOCIATED WITH LATISSE® USE? | LATISSE® solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower lid. If patients are using LUMIGAN® or other products in the same class for elevated intraocular pressure (IOP), or if they have a history of abnormal IOP, they should only use LATISSE® under the close supervision of their physician.
LATISSE® use may cause darkening of the eyelid skin, which may be reversible. LATISSE® use may also cause increased brown pigmentation of the colored part of the eye, which is likely to permanent. It is possible for hair growth to occur in other areas of the skin that LATISSE® frequently touches. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material to reduce the chance of this from happening. It is also possible for a difference in eyelash length, thickness, fullness, pigmentation, number of eyelash hairs, and/or direction of eyelash growth to occur between eyes. These differences, should they occur, will usually go away if the patient stops using LATISSE® solution.
WHAT ARE THE MOST COMMON SIDE EFFECTS OF LATISSE®? | The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
IS THERE POTENTIAL FOR IRIS DARKENING? | Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
WHAT IF PATIENTS STOP USING LATISSE®? | Patients’ lashes are expected to return to their previous appearance over several weeks to months.
WHY DO CONTACT LENSES NEED TO BE REMOVED BEFORE APPLYING? | It’s recommended that patients remove their contact lenses because LATISSE® contains benzalkonium chloride (BAK), and this may be absorbed by soft contact lenses. Contacts may be reinserted 15 minutes following LATISSE® administration.
CAN PATIENTS CONTINUE TO USE MASCARA WHILE USING LATISSE®? | Yes, patients can use mascara in addition to LATISSE® solution.
HOW SOON CAN PATIENTS EXPECT RESULTS? | It’s important for patients to remember that LATISSE® solution works gradually. While they may start seeing longer lashes after 4 weeks, to reach maximum fullness and darkness, they must use LATISSE® every day for 16 weeks. They should not reduce or stop daily application of LATISSE® when they first notice results, as they have yet to achieve full, dramatic effects. After 16 weeks, they should talk to their doctor about ongoing use. Individual results may vary
CAN PATIENTS USE COTTON SWABS OR OTHER COSMETIC BRUSHES TO APPLY LATISSE®? | No, LATISSE® should only be used with its FDA-approved sterile applicators, designed to help patients properly apply the product.
WHAT IF LATISSE® GETS IN A PATIENT’S EYE?| It is not expected to cause harm. Patients don’t need to rinse their eye. Reinforce the proper application instructions.
SOME IMPORTANT DO’S AND DON’TS:
• Do not apply to the lower lid or in the eye and blot excess solution with a tissue.
• Only use the sterile applicators supplied with LATISSE® to apply the product.
•Don’t allow the tip of the bottle or applicator to touch fingers or any other unintended surface, as contamination by common bacteria is known to cause infections.
•Remove contact lenses prior to applying LATISSE®. Contact lenses may be reinserted 15 minutes afterwards.
•Remember, if you stop using LATISSE®, lashes will gradually return to their previous appearance.
ADVERSE REACTIONS| The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
POSTMARKETING EXPERIENCE| The following reactions have been identified during postmarketing use of LATISSE® in clinical practice: burning sensation (eyelid), erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region), skin discoloration (periorbital), and vision blurred.
USE IN SPECIFIC POPULATIONS| Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
INDICATIONS| LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS| In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.
INDIVIDUAL RESULTS MAY VARY| If you stop using LATISSE®, your eyelashes are expected to return to their previous appearance over several weeks to months. Results may vary from eye to eye. There may be differences in eyelash length, thickness, fullness, pigmentation (darkness), number of eyelash hairs or the direction of eyelashes. If you experience any of these variations in your lashes, they will usually go away once you stop using LATISSE®.